|
|
1.
|
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. MedStar authors:
Year: 2016
Citation: - American Journal of Cardiovascular Drugs. 16(1):55-65, 2016 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Ballantyne CM, Barter PJ, Borgman M, Brewer HB, Herrman JP, Hu B, Kastelein JJ, Kataoka Y, Merkely B, Nicholls SJ, Nissen SE, Puri R, Uno K, Wolski K
|
|
|
2.
|
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. MedStar authors:
Year: 2017
Citation: - New England Journal of Medicine. 376(20):1933-1942, 2017 05 18
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - ACCELERATE Investigators, Barter PJ, Brewer HB, Conde D, Fox KAA, Gibson CM, Goodman SG, Granger C, Kandath D, Kouz S, Leiva-Pons JL, Li W, Lincoff AM, Mason D, McErlean E, McGuire DK, Menon V, Montalescot G, Nicholls SJ, Nicolau JC, Nissen SE, Pesant Y, Rader D, Riesmeyer JS, Ruotolo G, Tahirkheli N, Tall AR, Vangerow B, Weerakkody G, Wolski K
|
|
|
3.
|
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. MedStar authors:
Year: 2015
Citation: - Lancet. 386(9992):452-60, 2015 Aug 1.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Barter PJ, Brewer HB, Ford J, Hovingh GK, Kastelein JJ, Rader DJ, Round P, Saleheen D, van Deventer SJ
|
